Endocrinology, Vol 126, 1288-1294, Copyright © 1990 by Endocrine Society

ARTICLES

Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro

S Sandler, K Bendtzen, DL Eizirik and M Welsh
Department of Medical Cell Biology, Uppsala University, Sweden.

Recently it has been postulated that interleukin-1 (IL-1) locally released by infiltrating mononuclear cells may destroy the pancreatic B cells during the development of insulin-dependent diabetes mellitus. Since IL-1 is a potent inducer of interleukin-6 (IL-6) in various cells, it is conceivable that IL-6 is a second mediator of the IL-1 action. In the present study the effects of IL-6 alone or in combination with IL-1 were studied on pancreatic islet function in vitro after tissue culture and compared with the effects observed after exposure to IL-1 only. Rat pancreatic islets were cultured in medium RPMI 1640 + 10% calf serum with or without the addition of human recombinant IL-6 (500-5000 pg/ml) for 48 h. The medium insulin accumulation was increased by 40-50% after culture with 500-2000 pg/ml IL-6, but was similar to the controls at 5000 pg/ml. When islets were cultured for 18 h only, also 5000 pg/ml IL-6 stimulated the medium insulin accumulation. IL-6 did not affect the islet insulin content and the rates of islet (pro)insulin and total protein biosynthesis. It inconsistently decreased the islet DNA content. In short-term experiments after 48-h culture with IL-6, there was a dose-dependent inhibition of the glucose-stimulated insulin release. On the other hand, islets cultured with IL-6 (5000 pg/ml) exhibited an elevated glucose oxidation and oxygen uptake, but a lower ATP content at 16.7 mM glucose and an unaffected glucose utilization and glutamine oxidation compared to the controls. This raises the possibility that IL-6 had induced a condition with an increased energy expenditure, resulting in an enhanced mitochondrial metabolism of glucose. Islets cultured with human recombinant IL-1 beta (25 units/ml) showed a strong inhibition of the insulin accumulation in the culture medium and of glucose- stimulated insulin release and a marked decrease in the islet DNA and insulin content. A combination of IL-1 (25 U/ml) + IL-6 (1000 pg/ml) did not alter the inhibitory action of IL-1 alone. The present findings thus show that IL-6 induces a dissociation between insulin secretion and glucose oxidation in islets in vitro. This has not been observed in islets exposed to IL-1, which suggests that IL-6 does not solely mediate the inhibitory effects of IL-1 on islet function.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				O. P. Kristiansen and T. Mandrup-Poulsen Interleukin-6 and Diabetes: The Good, the Bad, or the Indifferent? Diabetes, December 1, 2005; 54(suppl_2): S114 - S124. [Abstract] [Full Text] [PDF]

				E. W. Petersen, A. L. Carey, M. Sacchetti, G. R. Steinberg, S. L. Macaulay, M. A. Febbraio, and B. K. Pedersen Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E155 - E162. [Abstract] [Full Text] [PDF]

				F. B. Stentz, G. E. Umpierrez, R. Cuervo, and A. E. Kitabchi Proinflammatory Cytokines, Markers of Cardiovascular Risks, Oxidative Stress, and Lipid Peroxidation in Patients With Hyperglycemic Crises Diabetes, August 1, 2004; 53(8): 2079 - 2086. [Abstract] [Full Text] [PDF]

				H.-J. Kim, T. Higashimori, S.-Y. Park, H. Choi, J. Dong, Y.-J. Kim, H.-L. Noh, Y.-R. Cho, G. Cline, Y.-B. Kim, et al. Differential Effects of Interleukin-6 and -10 on Skeletal Muscle and Liver Insulin Action In Vivo Diabetes, April 1, 2004; 53(4): 1060 - 1067. [Abstract] [Full Text] [PDF]

				H. Bays, L. Mandarino, and R. A. DeFronzo Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478. [Full Text] [PDF]

				J. M. Fernandez-Real and W. Ricart Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome Endocr. Rev., June 1, 2003; 24(3): 278 - 301. [Abstract] [Full Text] [PDF]

				A.D. Pradhan and P.M. Ridker Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur. Heart J., June 1, 2002; 23(11): 831 - 834. [Full Text] [PDF]

				A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus JAMA, July 18, 2001; 286(3): 327 - 334. [Abstract] [Full Text] [PDF]

				J.-M. Fernandez-Real, M. Vayreda, C. Richart, C. Gutierrez, M. Broch, J. Vendrell, and W. Ricart Circulating Interleukin 6 Levels, Blood Pressure, and Insulin Sensitivity in Apparently Healthy Men and Women J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1154 - 1159. [Abstract] [Full Text]

				C. Tsigos, D. A. Papanicolaou, I. Kyrou, R. Defensor, C. S. Mitsiadis, and G. P. Chrousos Dose-Dependent Effects of Recombinant Human Interleukin-6 on Glucose Regulation J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 4167 - 4170. [Abstract] [Full Text] [PDF]